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Background: Chagas disease (CD) is endemic in Latin America and particularly
common in Bolivia, but there is little information on the characteristics of
chronic digestive involvement.
Objectives: To determine the prevalence and characterize digestive manifestations
in chronic CD patients in Cochabamba, Bolivia.
Methods: Eighty-five T. cruzi-seropositive individuals with or without digestive
symptoms (G1 group), and fifteen T. cruzi-seronegative patients with similar
digestive symptoms to those seen in CD (G2 group) were included in the study.
All patients underwent a detailed history including past medical history,
epidemiological information, hygiene and dietary habits, a complete physical.e01206





Article Nowe01206examination, two serological tests for T. cruzi, video endoscopy, barium swallow,
and barium enema.
Findings: We observed digestive manifestations in T. cruzi seropositive and
seronegative patients. Colonic manifestations were detected in both groups,
highlighting the relevance of other confounder factors in the region. Constipation
was present in 52.9% of G1 patients, 62.4% presented two or more upper
digestive tract symptoms, and 5.9% of them presented esophageal manifestations.
Helicobacter pylori infection was detected in 58.8% of G1 patients, and all
patients presented gastritis on endoscopy.
Conclusions: Prevalence of digestive involvement in CD patients is higher than
expected. However, digestive symptoms are not always caused by T. cruzi
infection and require differential diagnoses.
Keyword: Infectious disease
1. Introduction
Chagas disease (CD), caused by the parasite Trypanosoma cruzi, is the main infec-
tious cause of heart disease in Latin America, where the disease is endemic [1]. It is
estimated that 20% of Bolivians have CD and the vector that transmits T. cruzi infec-
tion is endemic in 60% of the country [2]. The epidemiology of the disease has
changed due to migratory movements and T. cruzi infection is now considered a
global problem [3].
CD is primarily transmitted by a blood-sucking insect known as the kissing bug,
which is a member of the triatomine family. Triatoma infestans is the main vector
in Bolivia [3]. Other modes of transmission, less common but also important from
a public health perspective, are transmission by blood transfusion, organ transplant
from infected donors, and congenital from mother to infant, which can cause disease
spread in both endemic and traditionally non-endemic areas where triatomine bugs
do not exist [4]. There have also been reports of oral transmission in Amazon regions
[5]and urban environments [6].
Manifestations of chronic CD include heart damage (which affects 5%e30% of pa-
tients), digestive disorders (10%e20% of patients), and mixed and neurological al-
terations, which affect a smaller proportion of patients [7, 8, 9].
Gastrointestinal manifestations, which are the second most common cause of organ
complications in CD, are associated with high morbidity and can seriously affect pa-
tient’s quality of life. Although T. cruzi infection can affect all parts of the digestive
tract, the esophagus and the colon are most commonly involved.
Little is known about the characteristics of digestive damage in chronic CD pa-
tients in Bolivia, its association with specific genotypes of T. cruzi, and theon.2019.e01206





Article Nowe01206possible relation between the degree of affectation and the symptomatology pre-
sented by patients. The aim of this study was to determine the prevalence of diges-
tive manifestations and to characterize these in patients with CD in Cochabamba,
Bolivia.2. Materials and methods
A cross-sectional study was designed in which patients attending the Platform for the
Integral Care of Patients With CD over a 2-year period (December 2009eDecember
2011) were prospectively included. Patients were recruited in the department of Co-
chabamba, whose capital lies at a height of 2558 meters above sea level (m.a.s.l.).
Participation was voluntary and individual written informed consent was obtained
from all study participants.
A total of 100 patients were included in the study, divided into two groups.Group 1
(G1) included 85 patients with positive serology for T. cruzi infection with or
without digestive symptoms, and group 2 (G2) included 15 patients with negative
serology for T. cruzi infection but with similar digestive symptoms to those seen
in CD (11 patients had constipation, 2 had dysphagia, and 2 presented altered bowel
habit).
All patients underwent a full physical examination and a thorough history that
included past medical history, epidemiological information (place of origin, resi-
dence, contact with the insect vector that transmits T. cruzi infection), and hy-
giene and dietary habits. T. cruzi infection was diagnosed following detection
of antibodies to T.cruzi using two commercial serological tests: Weiner Lab
ELISA Chagatest Lisado and Weiner Lab ELISA Chagatest Recombinante (Ro-
sario Argentina). Patients with conflicting results underwent a third test with a
serology kit with high sensitivity and specificity (BioELISA Chagas, Biokit
S.A., Lliça d’Amunt, Barcelona, Spain). All patients were referred for barium
swallow and barium enema using the Rezende et al. and Ximenes et al. tech-
niques [10, 11].
Esophageal disease severity was classified using the criteria established by Ximenes
et al., which proposes a four group classification based on the results of the radiolog-
ical study [11]. The following colonic measurementsddefined as normaldwer-
eused to distinguish between normal and abnormal colon findings: rectosigmoid
colon of 6.5 cm (width) and 11e35 cm (length), 8 cm (width) and 25 cm (length)
for the ascending colon, and 12 cm (width) for the cecum [12, 13, 14, 15, 16].
All patients were referred for video endoscopy to check for the presence of gastric
disorders due to Helicobacter pylori infection or other causes. H. pylori infection
was diagnosed by histological examination of gastric biopsy specimens. G1 patientson.2019.e01206





Article Nowe01206underwent an electrocardiogram and routine laboratory tests defined in the protocol
for managing patients with T. cruzi infection at the Platform for the Integral Care of
Patients With CD. All patients who met the criteria for specific treatment were
offered benznidazole 5 mg/kg for 60 days.
Patients were also classified according to the altitude of their place of residence
(above or below 3000 m.a.s.l.) to control a confounding effect of megacolon at
high altitude [13, 15].
We analyzed means and standard deviations, ranges, and frequencies using SPSS
(SPSS Statistics 17.0.1- December 2008).
The study was reviewed and approved by a local ethics committee (CEADES Salud
y Medioambiente) and the ethics committee at Hospital Clínic in Barcelona, Spain.3. Results
A total of 100 patients were analyzed: 85 from G1 group and 15 from group G2.
Seventy-nine (93%) of the patients in G1 were women. The mean age of the patients
was 46 years-old (range, 20e64 years) and 21 (24.7%) lived above 3000 m.a.s.l. In
G2, there were 11 women (73%). The mean age of the group was 35 years-old
(range, 18e55 years) and 3 patients (20%) lived above 3000 m.a.s.l.
The analysis performed showed digestive involvement in 71.8% of G1 and 53.3% of
G2 patients. Colonic affectation was observed in 67% of all patients included in the
study, 6% presented esophageal manifestations, 100% presented some degree of
gastritis and 58.2% were positive for H. pylori infection. Results are summarized
in Table 1.
Colonic manifestations were detected in both groups. Barium enema results, taking
as main characteristic symptom constipation based on Roma III criteria ref, are
shown in Table 2. T. cruzi seropositive patients presented constipation in 52.9%
(45/85) of cases, and 41.2% (35/85) of them had abnormal barium enema findings.Table 1. Results of complementary studies performed in G1 and G2 patients.
G1 G2
Altered Not altered Altered Not altered
Digestive involvement with similar characteristics that digestive Chagas Disease radiological findings
Barium enema 60 25 7 8
Barium swallow 5 80 1 14
Digestive involvement (other than megaesophagus and megacolon)
Video endoscopy 84 0 14 0
Biopsy to determine H. pylori infection 50 34 7 7
on.2019.e01206
by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
censes/by-nc-nd/4.0/).
Table 2. Findings in patients presenting constipation and not presenting con-










Normal 10 9 6 1
Dolichocolon 6 3 0 1
Dolichomegacolon 22 21 2 0
Megacolon 7 7 3 2




Article Nowe01206According to the Ximenes and Rezende criteria [10], 67.1% (57/85) of patients in G1
presented criteria of colonic involvement due to Chagas disease (dolichomegacolon
and megacolon), and only 50.9% (29/57) of them presented constipation.
Fifty-four (63.5%) of the 85 patients in G1 had radiological findings consistent with
those caused by CD: dolichomegacolon (n¼ 27) and megacolon (n¼ 27). Of the 54
patients with manifestations consistent with those seen in CD, 13 (24.1%) lived
above 3000 m.a.s.l. In G2, 2/15 patients (13.3%) had findings consistent with CD:
megacolon (n ¼ 1) and dolichomegacolon (n ¼ 1). Neither of these patients lived
above 3000 m.a.s.l. Results are summarized in Table 3.
Symptoms associated with esophageal manifestations detected by barium swallow-
ing were dysphagia, regurgitation, retrosternal pain, heartburn, and abdominal
distension. 15% of all patients included in the study were asymptomatic and 56%
presented two or more symptoms. Similarly, 5 patients from group G1 presented
anormal barium swallowing results, and 4 of them presented at least one symptom.
Results are shown in Table 4.
The most common manifestations in T. cruzi seropositive patients were heartburn
(57.6%), abdominal distension (38.8%), retrosternal pain (27.1%), dysphagiaTable 3. Colonic manifestations in barium enema study by altitude of residence.
G1 G2
>3000 m.a.s.l. <3000 m.a.s.l. >3000 m.a.s.l. <3000 m.a.s.l.
Normal findings 6 (7.1%) 14 (16.5%) 2 (13.3%) 9 (60%)
Megacolon 6 (7.1%) 21 (24.7%) 0 (0%) 1 (6.6%)
Dolichomegacolon 7 (8.2%) 20 (23.5%) 0 (0%) 1 (6.6%)
Dolichocolon 2 (2.3%) 9 (10.6%) 1 (6.6%) 1 (6.6%)
Total 21 (24.7%) 64 (75.3%) 3 (20%) 12 (80%)
on.2019.e01206
by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
censes/by-nc-nd/4.0/).
Table 4. Esophageal involvement based on barium swallow study.
Asymptomatic One symptom Two symptoms Three or more
symptoms
G1
Normal findings 9 21 31 19
Grade I esophagopathy 1 1 1 0
Grade II esophagopathy 0 0 0 0
Grade III esophagopathy 0 0 1 0
Grade IV esophagopathy 0 0 0 1
G2
Normal findings 5 7 1 1
Grade I esophagopathy 0 0 1 0




Article Nowe01206(14.1%), regurgitation (7.1%) and odynophagia (2.4%). Results are summarized
in Table 5.
Four patients in G1 presented both esophageal and colonic manifestations: two had
megacolon and grade I and grade IV esophagopathy, and two had dolichomegacolon
and grade I and grade III esophagopathy. Out of total patients in G1 group, 71.8%
presented digestive manifestations, consistent with Ximenes and Rezende criteria
(56/85 colonic, 4/85 esophageal and colonic, and 1/85 esophageal).4. Discussion
Digestive disorders in CD patients in Cochabamba are more common than expected
based on prevalence rates reported for other countries (10e20% vs 68.2% in our se-
ries) [9, 15]. We also detected a high prevalence of digestive disorders in patients
without T. cruzi infection, although it should be noticed that these patients wereTable 5. Esophageal manifestations presented by T. cruzi infected and non-
infected patients.
G1 G2
Symptomatic Asymptomatic Symptomatic Asymptomatic
Dysphagia 12 73 2 13
Regurgitation 6 79 0 15
Odynophagia 2 83 0 15
Retrosternal pain 23 62 2 13
Heartburn 49 36 5 10
Abdominal distension 33 52 7 8
on.2019.e01206





Article Nowe01206selected because they had digestive symptoms, and therefore this observation cannot
be extrapolated to the general population. Nevertheless, the fact that patients without
CD presented similar esophageal and colonic manifestations to those seen in patients
with the disease, suggests that there might be other region-specific factors or disor-
ders at play. Previous studies have shown that, among other factors, prolonged stays
at high altitudes or chewing coca leaves for long periods of time can cause dolicho-
megacolon or megacolon [13, 17]. Cochabamba is a medium-high altitude city, on
the foothills of the Andes. However, internal migratory movements due to work are
frequent in Bolivia, and mobility of people between Cochabamba and other places at
higher altitude, as La Paz, Sucre or Potosi, are usual [18].
Based on the findings of our study, a large percentage of patients with CD in Cocha-
bamba have colon-related symptoms (67.06%) while esophageal manifestations are
lower (5.88%). Esophageal involvement is more common than colon involvement in
patients with T. cruzi infection in other countries in the Latin American region, such
as Argentina and Brazil [16]. In Bolivia, megaesophagus is more common in the
plains and foothills, while megacolon is more common in the plateaus and moun-
tainous regions. The above data, however, may be affected by confounders, such
as exposure to high altitudes, a high-fiber diet, or long-term chewing of coca leaves
in plateau areas of Bolivia, Chile, and Peru [17].
Altitude of place of residence is an important factor to consider. In our study, of the
total patients who lived at an altitude over 3000 m.a.s.l., 13 (61.9%) in G1 and
0 (0%) in G2 presented colonic manifestations. Despite the small number of pa-
tients in this study, particularly in G2, we detected colon disorders in both groups
of patients, showing that colon disorders are not necessarily associated with T.
cruzi infection.
The main abnormality detected in patients with high-altitude hypoxia is dolichome-
gacolon, which is diagnosed when the transverse rectosigmoid diameter is greater
than 6.5 cm. The presence of megacolon could be explained by Boyle’s Law, which
states that volume is inversely proportional to pressure [17, 19, 20, 21, 22]. Results
of an unpublished study conducted by Saravia and colleagues at the Bolivian Japa-
nese Gastroenterology Institute in Cochabamba show that intestinal volvulus is the
most common complication of megacolon in patients living at a mean altitude of
2560 m.a.s.l., where the average atmospheric pressure is 560 mbar (sea level pres-
sure of 760 mbar), the concentration of oxygen is 21%, and the partial pressure of
oxygen in arterial blood is 60e70 mmHg (90e100 mmHg at sea level). In our series,
dolichomegacolon was more common in patients living at an altitude of over 3000
m.a.s.l. (7/24 patients).
Another important confounder in this population is the long-term consumption of
coca leaves. Coca leaf chewing is a popular endemic activity throughout Bolivianon.2019.e01206





Article Nowe01206communities. Coca leaf are a mild stimulant, used for centuries due their charac-
teristics to alleviate altitude sickness and as an appetite suppressant [23]. Chew-
ing coca leaves can produce megacolon through the inactivation of adrenaline
metabolism in nerve endings, leading to progressive bowel wall ischemia with
secondary atrophy of the muscle layer, atony, gradual enlargement and extension
of the intestine, and a consequent reduction in intestinal activity [24, 25]. One
study of the histological features of the colon in patients with non-Chagasic meg-
acolon and a history of long-term ingestion of coca leaves reported the presence
of fat globules in large intestine muscle fibers in 80% of cases. The authors of
this study calculated that regular chewers of coca leaves were three times
more likely to develop fat globules in the intestinal track than other patients (p
< 0.05) [26].
The most common complications of megacolon are fecaloma, sigmoid volvulus, and
acute abdomen. In our series, in G1, one patient had a sigmoidectomy due to a
volvulus and two patients underwent surgical correction of a volvulus by
rectosigmoidoscopy.
We were unable to define the impact of confounding factors such as residence at high
altitudes or long-term consumption of coca leaves on the presence of megacolon,
due to the cross-sectional nature of our study. We were also unable to determine
whether or not patients living below 3000 m.a.s.l. had at some time lived at a higher
altitude.
All patients in G1 and G2 groups who underwent video endoscopy presented
different degree of gastritis. Histological examination revealed a high prevalence
of H. pylori infection in both groups: 58.8% (50 patients) in G1 and 50% (7 pa-
tients) in G2. According to data in the literature, H. pylori infection affects be-
tween 80% and 90% of people in developing countries and 50% of people
worldwide [22, 27]. The estimated prevalence in Bolivia is 50%e60% [28,
29], which is consistent with our findings. H. pylori infection causes a range
of non-specific symptoms that can be confused with those seen in T. cruzi-in-
fected patients with upper digestive manifestations [27]. The non- specificity
of T. cruzi infection symptoms poses a diagnostic challenge. In our study, several
patients in G1 with symptoms of CD had normal findings in the additional tests
performed, while in G2, several patients had symptoms suggestive of T. cruzi
infection but were not infected.5. Conclusions
Digestive disorders in patients with CD in Cochabamba, Bolivia, are more common
than would be expected. In our series, the colon was the most frequently affectedon.2019.e01206





Article Nowe01206segment of the digestive tract. The most common abnormalities detected in patients
with T. cruzi infection were megacolon and dolichomegacolon. However, colonic
manifestations were detected in both groups, suggesting that there might be other
region-specific factors. Overall, our findings suggest that symptoms typically seen
in patients with CD are not always caused by T. cruzi infection and require greater
investigation of alternative causes, such as concomitant infection by intestinal para-
sites, long-term consumption of coca leaves, megacolon at high altitude, and H. py-
lori infection.Declarations
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